6533b82ffe1ef96bd1294690
RESEARCH PRODUCT
Immunosenescence and Cytomegalovirus
Beatrix Grubeck-loebensteinTamas FulopDerek C. MacallanArne N. AkbarJan StrindhallSven D. KochPaul MossGerhard JahnCalogero CarusoEmanuelle TrannoyEvelyna DerhovanessianPeter C. L. BeverleyAndrea B. MaierGraham PawelecMark R. WillsKlaus HamprechtPaul D. GriffithsFlorian KernAnis LarbiSandrine I. Samsonsubject
lcsh:Immunologic diseases. AllergyAgingCMV ImmunosenescenceageingT cellImmunologyCongenital cytomegalovirus infectionYellow fever vaccine32 Biomedical and Clinical Scienceslcsh:GeriatricsVirusImmune systemMedicine3202 Clinical Sciencesbiologybusiness.industryvirus diseasesImmunosenescenceBiological Sciencesmedicine.disease3204 Immunologylcsh:RC952-954.6Ageingmedicine.anatomical_structureImmunologyT cell subsetQR180biology.proteinCommentaryAntibodylcsh:RC581-607businessmedicine.drugdescription
Since Looney at al. published their seminal paper a decade ago [1] it has become clear that many of the differences in T cell immunological parameters observed between young and old people are related to the age-associated increasing prevalence of infection with the persistent β-herpesvirus HHV-5 (Cytomegalovirus). Ten years later, studies suggest that hallmark age-associated changes in peripheral blood T cell subset distribution may not occur at all in people who are not infected with this virus [[2]; Derhovanessian et al., in press]. Whether the observed changes are actually caused by CMV is an open question, but very similar, rapid changes observed in uninfected patients receiving CMV-infected kidney grafts are consistent with a causative role [3]. This meeting intensively discussed these and other questions related to the impact of CMV on human immune status and its relevance for immune function in later life.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2010-09-07 | Immunity & ageing |